A price cap on insulin from drug company Sanofi  went into effect on New Year's Day, giving more Americans with diabetes more affordable treatments.  Sanofi cut the price of Lantus by 78% and Apidra by 70%.  These price cuts will reduce the cost of the drug for most patients at $35 through either price caps or savings programs.  Antonio Ciaccia is CEO of 46 Brooklyn Research.  A non-profit that researches drug pricing.  Ciaccia is On the Record with Steve Scott.

<p>A price cap on insulin from drug company Sanofi  went into effect on New Year's Day, giving more Americans with diabetes more affordable treatments.  Sanofi cut the price of Lantus by 78% and Apidra by 70%.  These price cuts will reduce the cost of the drug for most patients at $35 through either price caps or savings programs.  Antonio Ciaccia is CEO of 46 Brooklyn Research.  A non-profit that researches drug pricing.  Ciaccia is On the Record with Steve Scott.</p>
<p> </p>

Advertisement